French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development.

Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration ...

Sanofi is shelling out $1.15 billion to acquire Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform technology that will support the pharmaceutical giant’s ...

Sanofi said the deal for privately-held Vicebio includes an upfront payment of $1.15 billion and potential payments of up to $450 million subject to achieving certain development and regulatory ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K. The acquisition brings an early-stage combination vaccine ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology invented at the University of Queensland.